Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
ZUG, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor […]
MAG Silver Reports Preliminary 2024 Juanicipio Guidance
VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) — MAG Silver Corp. (TSX / NYSE American: MAG) (“MAG”, “MAG Silver”, […]
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2023 Results
BOSTON and ROLLE, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a […]
Matrix Service Company Receives Award From Long-Standing Client for Multiple Storage Tanks on the West Coast
TULSA, Okla., March 05, 2024 (GLOBE NEWSWIRE) — Matrix Service Company (Nasdaq: MTRX) announced today its subsidiary, Matrix North American Construction […]
Vivid Seats Reports Fourth Quarter Results and Authorizes New Share Repurchase Program
CHICAGO, March 05, 2024 (GLOBE NEWSWIRE) — Vivid Seats Inc. (NASDAQ: SEAT) (“Vivid Seats” or “we”), a leading marketplace that […]
NxuOne™ Makes History as the First Reported Third-Party Charging System to Harness Tesla Cybertruck’s 800V Architecture
MESA, Ariz., March 05, 2024 (GLOBE NEWSWIRE) — Nxu, Inc. (NASDAQ: NXU) (“Nxu”, “the company”), a domestic technology company specializing […]
Carbon Revolution To Present At The Emerging Growth Conference On Wednesday, March 6, 2024
GEELONG, Australia, March 05, 2024 (GLOBE NEWSWIRE) — Carbon Revolution plc (Nasdaq: CREV) (the “Company”), a Tier 1 OEM supplier […]
TSX News -
Hut 8 Operations Update for February 2024
Miami, March 05, 2024 (GLOBE NEWSWIRE) — Hut 8 Corp. (Nasdaq | TSX: HUT), (“Hut 8” or the “Company”) one of […]
LNG Energy Group Announces 2024 Production and Capital Guidance and Provides Operational Update
Highlights: Projected to generate between $33-39 million of EBITDA in 2024. Targeting 2024 exit rate gross operated production of between […]
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
Positive interim results from APG777 Phase 1 healthy volunteer clinical trial exceeded objectives with approximately 75-day half-life which supports the […]
